Home › Compare › DUVNF vs ABBV
DUVNF yields 1548.59% · ABBV yields 3.06%● Live data
📍 DUVNF pulled ahead of the other in Year 1
Combined, DUVNF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of DUVNF + ABBV for your $10,000?
Peruvian Metals Corp. engages in the acquisition, exploration for, and development of precious and base metals in Peru. The company holds 100% interests in the Panteria Porphyry Gold - Copper Project that consists of 4 mineral concessions covering an area of 2,000 hectares in south-central Peru; and the Cerro La Cumbre project consists of 2 mineral concessions covering an area of 727 hectares. It also has interests in the Huachocolpa properties that consist of 78 contiguous and non-contiguous mining concessions covering an area of 2,548 hectares located in the Department of Huancavelica; and the Palta Dorada property, which covers an area of 1,200 hectares located in the Ancash Mining Department in northern Peru; the Indio Inka property, which covers an area of 470 hectares located in asphalted road from the Aguila Norte processing plant; and the Minas Yanayco, which covers an area of 500 hectares located in Ancash Department near the small town of Pueblo Libre, as well as the Minas Visca project in northern Peru that covers an area of approximately 94 hectares. The company was formerly known as Duran Ventures Inc. and changed its name to Peruvian Metals Corp. in September 2018. Peruvian Metals Corp. was incorporated in 1997 and is based in Edmonton, Canada.
Full DUVNF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.